Life-threatening thrombocytosis following GCSF treatment in a case of clozapine-induced agranulocytosis.
Clozapine was introduced in European market in 1972 as an effective treatment for schizophrenia without extrapyramidal side effects. Within a short while, the clozapine story virtually came to a halt following detection of life-threatening neutropenia and agranulocytosis. Judicial use of granulocyte colony stimulating factor (GCSF) can be life saving with infrequent side effects in these cases. Here we are presenting a case of clozapine induced agranulocytosis managed with GCSF but had transient but life-threatening thrombocytosis, a very uncommon complication of GCSF therapy. Expression of GCSF receptors on the surface of megakaryocytic lineage is thought to be the cause of this unusual phenomenon.
Assam Medical College, Dibrugarh, Assam, India.
Sabita
S
Dihingia
Kamala
K
Deka
Dhrubajyoti
D
Bhuyan
Supriya Kumar
SK
Mondal
D000380:Agranulocytosis / Q000139:chemically induced*; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016638:Critical Illness; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007194:India; D008875:Middle Aged; D013922:Thrombocytosis / Q000139:chemically induced* / Q000503:physiopathology
D016179:Granulocyte Colony-Stimulating Factor; D003024:Clozapine